美国 · 交易所与实时行情 · Nasdaq
Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
Key PointsWhen evaluating the two companies based strictly on the most recent quarterly data, Eli Lilly currently shows a higher overall revenue base and a demonstrably faster…
在 Nasdaq 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.nasdaq.com)
